Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 128, Issue 12, Pages 5647-5662Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI97570
Keywords
-
Categories
Funding
- National Cancer Institute (NCI)
- NCI [R01-CA109322, R01-CA127483, R01-CA208703, U54-CA210181, R01-CA140243, R01-CA188610, U01 OH011328-02, T32-CA078207, F32-AI122715, T32-GM062754]
- NATIONAL CANCER INSTITUTE [R01CA188610, U54CA210181, R01CA208703, T32CA078207, R01CA204191, R01CA127483] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [U01OH011328] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM062754] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Tumor-associated myeloid cells maintain immunosuppressive microenvironments within tumors. Identification of myeloidspecific receptors to modulate tumor-associated macrophage and myeloid-derived suppressor cell (MDSC) functions remains challenging. The leukocyte immunoglobulin-like receptor B (LILRB) family members are negative regulators of myeloid cell activation. We investigated how LILRB targeting could modulate tumor-associated myeloid cell function. LILRB2 antagonism inhibited receptor-mediated activation of SHP1/2 and enhanced proinflammatory responses. LILRB2 antagonism also inhibited AKT and STAT6 activation in the presence of M-CSF and IL-4. Transcriptome analysis revealed that LILRB2 antagonism altered genes involved in cell cytoskeleton remodeling, lipid/cholesterol metabolism, and endosomal sorting pathways, as well as changed differentiation gene networks associated with inflammatory myeloid cells as opposed to their alternatively activated phenotype. LILRB2 blockade effectively suppressed granulocytic MDSC and Treg infiltration and significantly promoted in vivo antitumor effects of T cell immune checkpoint inhibitors. Furthermore, LILRB2 blockade polarized tumor-infiltrating myeloid cells from non-small cell lung carcinoma tumor tissues toward an inflammatory phenotype. Our studies suggest that LILRB2 can potentially act as a myeloid immune checkpoint by reprogramming tumorassociated myeloid cells and provoking antitumor immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available